Circulating tumor DNA (ctDNA) is a component of cell-free DNA (cfDNA) that is shed by
malignant tumors into the bloodstream and other bodily fluids. ctDNA can comprise up to …

Circulating cell free tumour DNA (ctDNA) maintains the same genomic alterations that are
present in the corresponding tumour, thereby allowing for quantitative and qualitative real …

Colorectal cancer (CRC) is frequently diagnosed at an advanced stage of the disease, the
pathogenesis of which is influenced by genetic and epigenetic events. Circulating tumor …

Background: Colorectal cancer is one of the most common cancers worldwide and has a
high mortality rate following disease recurrence. Treatment efficacy is maximized by …

There exists a tremendous opportunity in identifying and determining the appropriate
predictive and prognostic biomarker (s) for risk stratification of patients with colorectal …

Liquid biopsies that detect circulating tumour DNA (ctDNA) have the potential to
revolutionise the personalised management of colorectal cancer. For patients with early …

Background For patients with metastatic colorectal cancer, stratification for treatment
(surgery or chemotherapy) is often based on crude clinicopathological characteristics like …

Tumor biopsy is the standard method for cancer diagnosis and provides an important
sample for pathological assessment. With the development of precision medicine, liquid …

Characterization, diagnosis, and treatment of colorectal cancers (CRC) is difficult due to
limited biopsy information, impracticality of repeated biopsies, and cancer biomarker …

Background Increasingly, circulating tumor DNA (ctDNA) is proposed as a tool for minimal
residual disease (MRD) assessment. Digital PCR (dPCR) offers low analysis costs and …